Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 systems, which compromised their reliability and presented health risks to users [2]. - It is alleged that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to the devices [2]. - The company is accused of exposing itself to increased regulatory scrutiny and potential legal, reputational, and financial harm due to these actions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as a lead plaintiff in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].